Developer docs
API playgroundTry for free, no card

Search company profiles

Aldena Therapeutics

Full company profile

uuid00027oa

Namestring
Aldena Therapeutics
Legal namestring
Aldena Therapeutics
Websiteurl
aldenatherapeutics.com
Company typeenum
Private
Founded yearint
2021
Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
siRNA therapeutics, dermatology drug discovery, microneedle drug delivery, immuno-dermatology treatments, gene silencing therapies
Industry3 codes
1siRNA Therapeutics (gene silencing)
CodeHLAAADABPrimaryYes
2RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes)
CodeHLAAADADPrimaryNo
3RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
CodeHLAAADAGPrimaryNo
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Dermatology Biopharmaceuticals
No data
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Aldena Therapeutics develops a pipeline of siRNA-based (short interfering RNA) therapies targeting chronic dermatological diseases, specifically Atopic Dermatitis, Vitiligo, and Psoriasis. The company combines its siRNA therapeutic platform with proprietary microneedle delivery technology designed to overcome skin barrier challenges and enable long-lasting, gene-silencing treatments for skin conditions.

Differentiator
Functional benefit
Problem solved
Product and service4 records
1siRNA-based Therapy for Atopic Dermatitis
CategoryDrug candidate
2siRNA-based Therapy for Vitiligo
CategoryDrug candidate
3siRNA-based Therapy for Psoriasis
CategoryDrug candidate
4Microneedle Delivery Technology
CategoryDrug delivery platform
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Peers10 records
1Alys Pharmaceuticals
TypeDirect peer
Description

Parent company of Aldena Therapeutics. Alys is a dermatology-focused platform that has absorbed Aldena's siRNA assets; operates in the same therapeutic area (skin disease) and provides the corporate context for Aldena's pipeline.

2Alnylam Pharmaceuticals
TypeBroad incumbent
Description

The leading clinical-stage siRNA platform company with approved products (Onpattro, Givlaari, Oxlumo, Amvuttra). Comparable because it defines the siRNA modality Aldena uses, though Alnylam targets liver and systemic indications rather than dermatology.

3Arrowhead Pharmaceuticals
TypeDirect peer
Description

Clinical-stage siRNA therapeutics company with multiple partnered programs (including in dermatology-relevant indications). Directly comparable as an siRNA platform player pursuing tissue-targeted gene silencing.

4Viridian Therapeutics
TypeEmerging player
Description

Clinical-stage company developing RNA-based therapies for autoimmune and rare diseases, with growing dermatology interest. Comparable as an emerging player using nucleic-acid-based approaches in skin/autoimmune indications.

5Arcturus Therapeutics
TypeDirect peer
Description

RNA therapeutics company developing mRNA and siRNA candidates with proprietary delivery technology. Comparable for its RNA platform approach and emphasis on novel delivery, though targeting different therapeutic areas.

6Wave Life Sciences
TypeEmerging player
Description

Clinical-stage nucleic acid therapeutics company with siRNA and other RNA programs. Comparable as a peer in RNA-based drug development with stereopure oligonucleotide chemistry.

7Arbutus Biopharma
TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing siRNA and oral RNA interference therapeutics. Comparable as an siRNA platform peer with proprietary delivery technology (GalNAc conjugation).

8Dermavant Sciences
TypeDirect peer
Description

Dermatology-focused biopharma developing innovative therapies for skin diseases including psoriasis and atopic dermatitis. Comparable as a direct competitor in the same dermatology therapeutic area as Aldena's pipeline.

9AnaptysBio
TypeDirect peer
Description

Clinical-stage immunology company developing antibodies for inflammatory skin diseases including atopic dermatitis. Comparable as a direct peer developing novel therapeutics for the same dermatology indications.

10Galderma
TypeBroad incumbent
Description

Global dermatology-focused pharmaceutical company with broad portfolio across skin conditions including atopic dermatitis, psoriasis, and acne. Comparable as a broad incumbent in the dermatology therapeutics space where Aldena's pipeline operates.

Market position
Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aldena Therapeutics

Dermatology Biopharmaceuticalsaldenatherapeutics.com

Aldena Therapeutics firmographics

Firmographics
Name
Aldena Therapeutics
Legal name
Aldena Therapeutics
Website
https://aldenatherapeutics.com
Company type
Private
Founded year
2021
Operating status
Acquired
Headcount range
1–10 employees
Ownership category
akta.pro rank

Aldena Therapeutics industry classification

Industry
Product category
Dermatology Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro primary industry
siRNA Therapeutics (gene silencing) (HLAAADAB)
akta.pro secondary industries
RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes) (HLAAADAD), RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)

Keywords

  • SiRNA therapeutics
  • Dermatology drug discovery
  • Microneedle drug delivery
  • Immuno-dermatology treatments
  • Gene silencing therapies

Where Aldena Therapeutics is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Markets served

Aldena Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure

Marketing channels1 record

Aldena Therapeutics product offering

Product offering

Core offering

Aldena Therapeutics develops a pipeline of siRNA-based (short interfering RNA) therapies targeting chronic dermatological diseases, specifically Atopic Dermatitis, Vitiligo, and Psoriasis. The company combines its siRNA therapeutic platform with proprietary microneedle delivery technology designed to overcome skin barrier challenges and enable long-lasting, gene-silencing treatments for skin conditions.

Differentiator

Problem solved

Functional benefit

Products and services

  • siRNA-based Therapy for Atopic Dermatitis
  • siRNA-based Therapy for Vitiligo
  • siRNA-based Therapy for Psoriasis
  • Microneedle Delivery Technology

Companies that use Aldena Therapeutics

Customer profile

Segments1 record

Ideal customer profiles2 records

Aldena Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Aldena Therapeutics partnerships and signals

Strategic signal

Scale indicators3 records

Aldena Therapeutics competitors and assessment

Company assessment

Direct peers

  • Alys Pharmaceuticals: Parent company of Aldena Therapeutics. Alys is a dermatology-focused platform that has absorbed Aldena's siRNA assets; operates in the same therapeutic area (skin disease) and provides the corporate context for Aldena's pipeline.
  • Arrowhead Pharmaceuticals: Clinical-stage siRNA therapeutics company with multiple partnered programs (including in dermatology-relevant indications). Directly comparable as an siRNA platform player pursuing tissue-targeted gene silencing.
  • Arcturus Therapeutics: RNA therapeutics company developing mRNA and siRNA candidates with proprietary delivery technology. Comparable for its RNA platform approach and emphasis on novel delivery, though targeting different therapeutic areas.
  • Arbutus Biopharma: Clinical-stage biopharmaceutical company developing siRNA and oral RNA interference therapeutics. Comparable as an siRNA platform peer with proprietary delivery technology (GalNAc conjugation).
  • Dermavant Sciences: Dermatology-focused biopharma developing innovative therapies for skin diseases including psoriasis and atopic dermatitis. Comparable as a direct competitor in the same dermatology therapeutic area as Aldena's pipeline.
  • AnaptysBio: Clinical-stage immunology company developing antibodies for inflammatory skin diseases including atopic dermatitis. Comparable as a direct peer developing novel therapeutics for the same dermatology indications.

Broad incumbents

  • Alnylam Pharmaceuticals: The leading clinical-stage siRNA platform company with approved products (Onpattro, Givlaari, Oxlumo, Amvuttra). Comparable because it defines the siRNA modality Aldena uses, though Alnylam targets liver and systemic indications rather than dermatology.
  • Galderma: Global dermatology-focused pharmaceutical company with broad portfolio across skin conditions including atopic dermatitis, psoriasis, and acne. Comparable as a broad incumbent in the dermatology therapeutics space where Aldena's pipeline operates.

Emerging players

  • Viridian Therapeutics: Clinical-stage company developing RNA-based therapies for autoimmune and rare diseases, with growing dermatology interest. Comparable as an emerging player using nucleic-acid-based approaches in skin/autoimmune indications.
  • Wave Life Sciences: Clinical-stage nucleic acid therapeutics company with siRNA and other RNA programs. Comparable as a peer in RNA-based drug development with stereopure oligonucleotide chemistry.

Market position

Customer concentration

Aldena Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aldena Therapeutics leadership team

Management profile

Number of profiles

Aldena Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aldena Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aldena Therapeutics

What does Aldena Therapeutics do?

Aldena Therapeutics develops a pipeline of siRNA-based (short interfering RNA) therapies targeting chronic dermatological diseases, specifically Atopic Dermatitis, Vitiligo, and Psoriasis. The company combines its siRNA therapeutic platform with proprietary microneedle delivery technology designed to overcome skin barrier challenges and enable long-lasting, gene-silencing treatments for skin conditions.

Is Aldena Therapeutics a public or private company?

Aldena Therapeutics is a private company. It is classified as corporate owned and is currently acquired.

When was Aldena Therapeutics founded?

Aldena Therapeutics was founded in 2021. It employs 1 to 10 people.

Where is Aldena Therapeutics based?

Aldena Therapeutics is headquartered in Boston, United States, in the North America region.

Who are Aldena Therapeutics's main competitors?

Direct peers on record are Alys Pharmaceuticals, Arrowhead Pharmaceuticals, Arcturus Therapeutics, Arbutus Biopharma, Dermavant Sciences and AnaptysBio. Broad incumbents are Alnylam Pharmaceuticals and Galderma. Emerging players are Viridian Therapeutics and Wave Life Sciences.

Does Aldena Therapeutics have an API?

No public API is recorded for Aldena Therapeutics.

What industry is Aldena Therapeutics in?

Aldena Therapeutics's product category is Dermatology Biopharmaceuticals. Its primary akta.pro industry code is HLAAADAB, siRNA Therapeutics (gene silencing), with a secondary code of HLAAADAD, RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireAldena Therapeutics Accelerates its Novel and Disruptive Approach to Immuno-DermatologyAldena Therapeutics announced a US$30 million financing round led by Medicxi and the appointment of a Scientific Advisory Board chaired by Nobel Laureate Craig Mello. The company aims to develop siRNA-based therapies for dermatological conditions such as Atopic Dermatitis and Psoriasis, with three compounds expected to be ready for IND filing next year. This investment supports Aldena's disruptive transepidermal delivery approach to immuno-dermatology.PR NewswireAldena Therapeutics Accelerates its Novel and Disruptive Approach to Immuno-DermatologyAldena Therapeutics Inc. has announced an update on its pipeline of siRNA-based therapies for dermatological diseases, supported by a US$ 30 million investment from Medicxi. The company aims to advance treatments for various skin conditions using a novel method of drug delivery that enhances the therapeutic potential of established modes of action. Under the leadership of CEO Thibaud Portal, Aldena plans to have three compounds ready for IND filing next year.HubsAldena Raises $30M to Advance Skin-Deep siRNA TherapiesBoston-based biotech Aldena Therapeutics has raised $30 million from investment firm Medicxi to accelerate the development of its siRNA-based therapies for immuno-dermatology indications. The funding will support Aldena's efforts to prepare its lead assets for clinical entry within the next two years, leveraging proprietary microneedle technology to deliver treatments for conditions like psoriasis and atopic dermatitis. This financial boost aims to de-risk the company's technology and advance six candidates toward Investigational New Drug applications.